Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504376 | 0.91 | GRM4 (0.41) | HSP90AA1HSP90AB1CNR2HTR7ESR1 | |
| SCHEMBL6957700 | 0.84 | DRD3 (0.45) | ALDH1A1GAA | |
| SCHEMBL3505352 | 0.83 | LMNA (0.42) | HTR7GRM4ALDH1A1GAALMNA | |
| SCHEMBL3505500 | 0.77 | ALDH1A1 (0.43) | CNR2ALDH1A1CNR1 | |
| SCHEMBL9386764 | 0.77 | LMNA (0.37) | HSP90AA1HSP90AB1GRM4ALDH1A1GAA | |
| SCHEMBL3508760 | 0.74 | HTR2A (0.39) | HTR7ALDH1A1 | |
| SCHEMBL6953674 | 0.74 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1ALDH1A1CNR1LMNA | |
| SCHEMBL3505067 | 0.73 | ACHE (0.40) | GRM4ALDH1A1GAALMNA | |
| SCHEMBL3510105 | 0.72 | ALDH1A1 (0.50) | HSP90AA1HSP90AB1ALDH1A1GAALMNA | |
| SCHEMBL8947062 | 0.72 | ACHE (0.42) | ALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5494908-A | ANTIDEPRESSANT | HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) | 1996-02-27 | — | — | US | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| EP-0669920-B1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | AVENTIS PHARMA INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6046203-A | USEFUL FOR THE TREATMENT OF VARIOUS MEMORY DYSFUNCTIONS CHARACTERIZED BY A DECREASED CHOLINERGIC FUNCTION SUCH AS ALZHEIMER'S DISEASE; ALSO INHIBIT MONOAMINE OXIDASE AND HENCE ARE USEFUL AS ANTIDEPRESSANTS | AVENTIS PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5580982-A | ANTIDEPRESSANTS; ANTICHOLINERGIC AGENTS; ALZHEIMER'S DISEASE; AMINE OXIDASE INHIBITORS | HOECHST MARION ROUSSEL INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5494908-A | ANTIDEPRESSANT | HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) | 1996-02-27 | — | — | US | disclosed |
| WO-1994012495-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-06-09 | — | — | WO | disclosed |